Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C

Hepatology Research

Volumn 40, Issue 4, 2010, Pages 383-392

  Arima, Yuko ^a   Kawabe, Naoto ^a   Hashimoto, Senju ^a   Harata, Masao ^a   Nitta, Yoshifumi ^a   Murao, Michihito ^a   Nakano, Takuji ^a   Shimazaki, Hiroaki ^a   Kobayashi, Kyoko ^a   Ichino, Naohiro ^a   Osakabe, Keisuke ^a   Nishikawa, Toru ^a   Okumura, Akihiko ^b   Ishikawa, Tetsuya ^c   Yoshioka, Kentaro ^a  

^a FUJITA HEALTH UNIVERSITY   (Japan)

^b Kainan Hospital   (Japan)

^c Nagoya Kyoritsu Hospital   (Japan)

Author keywords

Non virological response; Relapser; Ribavirin; Sustained virological response; Transient elastography

Indexed keywords

ALANINE AMINOTRANSFERASE; CONSENSUS INTERFERON; HYALURONIC ACID; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; DISEASE COURSE; DRUG EFFECT; ELASTOGRAPHY; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; SEX DIFFERENCE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

EID: 77954369431     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00618.x     Document Type: Article

References (43)

1. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997, 26:62S-65S.
2. Di Bisceglie AM. Hepatitis C. Lancet 1998, 351:351-5.
3. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999, 31(1):9-16. Suppl
4. Poynard T, Leroy V, Cohard M. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996, 24:778-89.
5. Davis GL, Esteban-Mur R, Rustgi V. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1493-9.
6. Fried MW, Shiffman ML, Reddy KR. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-82.
7. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998, 28:1121-7.
8. Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999, 30:783-7.
9. Poynard T, McHutchison J, Davis GL. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000, 32:1131-7.
10. Poynard T, McHutchison J, Manns M. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 122:1303-13.
11. Saracco G, Rosina F, Abate ML. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b. Hepatology 1993, 18:1300-5.
12. Tsubota A, Kumada H, Chayama K. Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C virus infection. J Hepatol 1997, 27:49-55.
13. Camma C, Di Marco V, Lo Iacono O. Long-term course of interferon-treated chronic hepatitis C. J Hepatol 1998, 28:531-7.
14. Shiratori Y, Imazeki F, Moriyama M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000, 132:517-24.
15. Veldt BJ, Saracco G, Boyer N. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004, 53:1504-8.
16. Toccaceli F, Laghi V, Capurso L, Koch M, Sereno S, Scuderi M. Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon. J Viral Hepat 2003, 10:126-33.
17. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009, 49:729-38.
18. Camma C, Di Bona D, Schepis F. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004, 39:333-42.
19. Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 2004, 127:S294-302.
20. Ikeda K, Saitoh S, Suzuki Y. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998, 28:930-8.
21. Zaman A, Hapke R, Flora K, Rosen HR, Benner K. Factors predicting the presence of esophageal or gastric varices in patients with advanced liver disease. Am J Gastroenterol 1999, 94:3292-6.
22. Regev A, Berho M, Jeffers LJ. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614-18.
23. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-57.
24. Sandrin L, Fourquet B, Hasquenoph JM. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003, 29:1705-13.
25. Castera L, Vergniol J, Foucher J. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-50.
26. Ziol M, Handra-Luca A, Kettaneh A. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005, 41:48-54.
27. Colletta C, Smirne C, Fabris C. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005, 42:838-45.
28. Ganne-Carrie N, Ziol M, de Ledinghen V. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006, 44:1511-17.
29. Corpechot C, El Naggar A, Poujol-Robert A. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006, 43:1118-24.
30. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-93.
31. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991, 13:372-4.
32. Ishak K, Baptista A, Bianchi L. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-9.
33. Friedenberg MA, Miller L, Chung CY. Simplified method of hepatic fibrosis quantification: design of a new morphometric analysis application. Liver Int 2005, 25:1156-61.
34. Lazzarini AL, Levine RA, Ploutz-Snyder RJ, Sanderson SO. Advances in digital quantification technique enhance discrimination between mild and advanced liver fibrosis in chronic hepatitis C. Liver Int 2005, 25:1142-9.
35. Goodman ZD, Becker RL, Pockros PJ, Afdhal NH. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology 2007, 45:886-94.
36. Arima M, Terao H, Kashima K, Arita T, Nasu M, Nishizono A. Regression of liver fibrosis in cases of chronic liver disease type C: quantitative evaluation by using computed image analysis. Intern Med 2004, 43:902-10.
37. Yoshioka K, Kawabe N, Hashimoto S. Transient elastography: applications and limitations. Hepatol Res 2008, 38:1063-8.
38. Coco B, Oliveri F, Maina AM. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007, 14:360-9.
39. Sagir A, Erhardt A, Schmitt M, Haussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 2008, 47:592-5.
40. Arena U, Vizzutti F, Corti G. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008, 47:380-4.
41. Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res 2009, 83:127-34.
42. Nitta Y, Kawabe N, Hashimoto S. Liver stiffness measured by transient elastography correlates with fibrosis area in liver biopsy in patients with chronic hepatitis C. Hepatol Res 2009, 39:675-84.
43. Vergniol J, Foucher J, Castera L. Changes of non-invasive markers and FibroScan values during HCV treatment. J Viral Hepat 2009, 16:132-40.